To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
To evaluate the clinical benefit of switching to quetiapine sustained release (SR) in patients with schizophrenia experiencing suboptimal efficacy/tolerability with their current antipsychotic.
This was a 12-week, multicentre, open-label study (D1444C00147). Quetiapine SR (mg/day) was initiated during a 4-day cross titration phase (300 on Day 1; 600 on Day 2; 400, 600 or 800 on Day 3; flexible-dosing [400-800] from Days 4-84). Primary objective was to demonstrate that >50% of patients would achieve clinical benefit (improved CGI-Clinical Benefit [CB] score, based on CGI-I Efficacy index and tolerability burden) at Week 12. Secondary endpoints included CGI-I and PANSS total scores. Tolerability was assessed by adverse events (AEs), SAS and BARS scores. Mean changes in rating scale scores were analysed using ANCOVA.
477 patients were switched to quetiapine SR, 370 (77.6%) completed treatment. 295 of 470 evaluable patients (62.8%) achieved a clinical benefit upon switching to quetiapine SR (95% CI 58.4, 67.1, p<0.0001). Significant improvements were observed in mean [SD] change from baseline in CGI-CB (-2.1 [3.62]) and PANSS total (-13.6 [19.23]) (both p<0.001). Mean [SD] CGI-I score at endpoint was 2.8 [1.49] (p<0.001 for mean CGI-I<4). Common AEs included somnolence (17.8%), sedation (15.1%), dizziness and dry mouth (14.0% each). The incidence of EPS was 8.0%. Mean changes (improvements) from baseline in SAS and BARS scores were -2.1 and -0.4 respectively (both p<0.001).
Switching to quetiapine SR was associated with clinical benefit and was well tolerated in patients with schizophrenia experiencing suboptimal efficacy/tolerability with their previous antipsychotic treatment.
Assess the efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) in patients with schizophrenia and depressive symptoms.
12-week, multi-centre, open-label study in adult patients with schizophrenia (D1444C00147). Patients were cross titrated to quetiapine XR over three days (Day 1: 300 mg; Day 2: 600 mg; Days 3-84: 400-800 mg/day [flexible dosing]). Two patient subsets: high depression symptoms (PANSS depression cluster score ≥ 12) and low depression symptoms (PANSS depression cluster score < 12) at baseline. Change from baseline of PANSS total score and PANSS depression cluster score were analysed by subgroup.
Mean (SD) change at Day 84 (LOCF) in PANSS depression cluster score was -4.8 (3.3) for patients with high depression (n=109) and -1.1 (2.7) for patients with low depression (n=362). Mean (SD) change from baseline at Day 84 (LOCF) in PANSS total score was -24.3 (18.5) for patients with high depression and -10.5 (18.0) for patients with low depression. at Day 84: in patients switched to quetiapine XR owing to “lack of efficacy”, mean change (SD) from baseline in PANSS depression cluster score was -5.2 (3.2) and -1.3 (2.8) for patients with high and low depression, respectively; in patients switched due to “insufficient tolerability”, mean change (SD) in PANSS depression cluster score was -4.1 (3.5) and -0.6 (2.5) for patients with high and low, respectively.
Quetiapine XR showed promising results in patients with schizophrenia and depressive symptoms switched from other antipsychotics due to suboptimal efficacy or tolerability. Further randomised, clinical trials are warranted.
The species of the tree genus Pterospermum Schreb. (Malvaceae: Dombeyoideae) in Malesia are revised. Twenty-six species of Pterospermum are recognised, six of which are new (P. aureum S.K.Ganesan, P. borneense S.K.Ganesan, P. glabrum S.K.Ganesan, P. havilandii S.K.Ganesan, P. merrillianum S.K.Ganesan and P. zollingerianum S.K.Ganesan) and one (P. grewiifolium Pierre) that is a new distributional record for Malesia. Identification keys are provided. All names are typified, and detailed descriptions of all species recognised are provided. Information on habitat, uses and conservation status is given for all species.
Application of CHG-impregnated or control (Comfort Bath; Sage) cloths applied over entire body thrice weekly.
Recruits were monitored daily for SSTI. Baseline and serial nasal and/or axillary swabs were collected to assess S. aureus colonization.
Of 1,562 subjects enrolled, 781 (from 23 platoons) underwent CHG-impregnated cloth application and 781 (from 21 platoons) underwent control cloth application. The rate of compliance (defined as application of 50% or more of wipes) at 2 weeks was similar (CHG group, 63%; control group, 67%) and decreased over the 6-week period. The mean 6-week SSTI rate in the CHG-impregnated cloth group was 0.094, compared with 0.071 in the control group (analysis of variance model rate difference, 0.025 ± 0.016; P = .14). At baseline, 43% of subjects were colonized with methicillin-susceptible S. aureus (MSSA), and 2.1% were colonized with MRSA. The mean incidence of colonization with MSSA was 50% and 61% (P = .026) and with MRSA was 2.6% and 6.0% (P = .034) for the CHG-impregnated and control cloth groups, respectively.
CHG-impregnated cloths applied thrice weekly did not reduce rates of SSTI among recruits. S. aureus colonization rates increased in both groups but to a lesser extent in those assigned to the CHG-impregnated cloth Intervention. Antecedent S. aureus colonization was not a risk factor for SSTI. Additional studies are needed to identify effective measures for preventing SSTI among military recruits.
Division XI connects astronomers using space techniques or particle detectors for an extremely large range of investigations, from in-situ studies of bodies in the solar system to orbiting observatories studying the Universe in wavelenghts ranging from radio waves to γ-rays, to underground detectors for cosmic neutrino radiation.
This paper investigates the optical properties of bulk and epitaxial ZnO layers. High quality undoped and doped bulk ZnO crystals have been produced by melt growth techniques in addition to ZnO thin films grown by Metalorganic Chemical Vapor Deposition (MOCVD) on silicon, sapphire and the bulk ZnO substrates. This work focuses on investigating the suitability of bulk and epitaxial ZnO for waveguide applications using various spectroscopic techniques. The photoluminescence showed the dominance of strong and narrow band due to the band edge emissions for undoped ZnO. Ultraviolet-visible transmission data revealed the variation of the bandgap with different doping elements. Raman spectra showed a narrow and strong peak, corresponding to the E2 mode at 438 cm-1, characteristic of the ZnO crystallinity. A broad 2LO peak appeared near 1150 cm-1 due to the coupling between LO phonons and free carriers. A clear variation in refractive index with doping was observed by spectroscopic ellipsometery suggesting that ZnO could be used for waveguide applications.
Facial palsy in the presence of ipsilateral parotid tumour is considered to be pathognomonic of malignancy. However, benign neoplasms and inflammatory lesions of the parotid gland have been reported to present with facial palsy. A case of lipoma of the parotid gland associated with partial facial paralysis is reported. Lipomas are very rarely seen in this site. To our knowledge, a lipoma of the parotid producing facial paralysis has not been described previously. This report highlights the difficulties in pre-operative diagnosis and management of such a lesion.
We have conducted x-ray diffraction, Raman spectroscopy, and scanning electron microscopy analyses of diamond films grown by hot filament assisted chemical vapor deposition (HFCVD). We present results on the relative abundance of the (111), (220) and (400) faces in polycrystalline diamond films as functions of CH4 concentration. The intensity of the (111) peak can be varied from about 20% to 60% by adjusting CH4 in CH4/H2 mixtures. We also present results on preferred orientation in films grown under varying hydrogen treatments. We discuss correlations between the preferred orientation, FWHM of the diamond peak in the Raman spectrum, and surface morphology of the films.
Email your librarian or administrator to recommend adding this to your organisation's collection.